Fibrinolytic response to exercise in women using third-generation oral contraceptives

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 7, 2006, Pages 563-568

  Weiss, Claus ^a   Walter, Birgit ^a   Dorsch, Micha F ^a   Bärtsch, Peter ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

D dimer; Fibrinolysis; Plasmin antiplasmin complexes; Plasminogen activator inhibitor 1; Tissue type plasminogen activator

Indexed keywords

ANTIGEN; ANTIPLASMIN; D DIMER; DESOGESTREL; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANAEROBIC THRESHOLD; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXERCISE; EXERCISE TEST; FEMALE; FIBRINOLYSIS; HUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS; TREADMILL; VELOCITY;

ADULT; ANTIPLASMIN; CONTRACEPTIVES, ORAL; EXERCISE; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HEART RATE; HUMANS; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33748921414     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000245301.10387.83     Document Type: Article

References (27)

1. Gerstmann BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of venous thrombembolic disease. Am J Epidemiol 1991; 133:32-37.
2. Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thrombembolism: a quantitative discussion of the uncertainties. J Intern Med 1995; 238:31-37.
3. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thrombembolic disease and combined oral contraceptives: results of international multicenter case-control study. Lancet 1995; 346:1575-1582.
4. Cachrimanidou AC, Hellberg D, Nilsson S, von Schoulz B, Crona N, Siegbahn A. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive. Contraception 1994; 50:153-165.
5. Meijers JCM, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis. Thromb Haemost 2000; 84:9-14.
6. Norris LA, Bonnar J. The effect of oestrogen dose and progesteron type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol 1996; 103:261-267.
7. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78:315-326.
8. Parmer RJ, Mahata M, Mahata S, Sebald MT, O'Connor DT, Miles LA. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. J Biol Chem 1997; 272:1976-1982.
9. Van den Eijnden-Schrauwen Y, Kooistra T, de Vries REM, Emeis JJ. Studies on acute release of tissue type plasminogen-activator from endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. Blood 1995; 85:3510-3517.
10. Bourey RE, Santoro SA. Interactions of exercise, coagulation, platelets, and fibrinolysis - a brief review. Med Sci Sports Exerc 1998; 20:439-446.
11. Walter B, Weiss C, Dorsch M, Bärtsch P. Exercise-induced fibrin formation is enhanced in women using third-generation oral contraceptives. J Thromb Haemost 2006; 4:898-899.
12. Stegmann H, Kindermann W, Schnabel A. Lactate kinetics and individual anaerobic threshold. Int J Sports Med 1981; 2:160-165.
13. Weiss C, Bierhaus A, Kinscherf R, Hack V, Luther T, Nawroth PP, Bärtsch P. Tissue factor-dependent pathway is not involved in exercise-induced formation of thrombin and fibrin. J Appl Physiol 2002; 92:211-218.
14. Weiss C, Seitel G, Bärtsch P. Coagulation and fibrinolysis after moderate and exhaustive exercise in healthy male subjects. Med Sci Sports Exerc 1998; 30:246-251.
15. Weiss C, Egermann M, Bärtsch P. Exercise-induced activation of coagulation in subjects with activated protein C resistance. Blood Coagul Fibrinol 2004; 15:317-321.
16. Dill DB, Costill DL. Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol 1974; 37:247-248.
17. Scarabin P-Y, Plu-Bureau G, Zitoun D, Bara L, Guize L, Samama MM. Changes in haemostatic variables induced by oral contraceptives containing 50 mg or 30 mg oestrogen: absence of dose-dependent effect on PAI-1 activity. Thromb Haemost 1995; 74:928-932.
18. Task Force on Oral Contraceptives - WHO Special programme of Research, Development and Research Training in Human Reproduction. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Br J Obstet Gynaecol 1991; 98:1117-1128.
19. Girolami A, Paolo S, Bruno G, Luigi S. Oral contraceptive therapy causes an increased and not a decreased resistance to APC. Blood Coag Fibrinol 1995; 6:143-144.
20. Henkens CMA, Bom VJJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 1995; 73:402-404.
21. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91:1952-1958.
22. Petersen KR, Sidelmann J, Skouby SO, Jespersen J. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gynecol 1993; 168:32-38.
23. Quehenberger P, Kapiotis S, Pärtan C, Schneider B, Wenzel R, Gaiger A, et al. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells. Ann Hematol 1993; 67:33-36.
24. Lansink M, Jong M, Bijsterbosch M, Bekkers M, Toet K, Havekes L, et al. Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced manose receptor expression in mice. Blood 1999; 94:1330-1336.
25. De Paz JA, Villa JG, Vilades E, Martin-Nuno MA, Lasierra J, Gonzales-Gallego J. Effects of oral contraceptives on fibrinolytic response to exercise. Med Sci Sports Exerc 1995; 27:961-966.
26. Hoetzer GL, Stauffer BL, Greiner JJ, Casas J, Smith DT, Desouza CA. Influence of oral contraceptive use on endothelial t-PA release in healthy premenopausal women. Am J Physiol Endocrinol Metab 2003; 284:E90-E95.
27. Van den Burg PJM, Dooijewaard G, van Vliet M, Mosterd WL, Kluft C, Huisveld IA. Differences in u-PA and t-PA increase during acute exercise: relation with exercise parameters. Thromb Haemost 1994; 71:236-239.